prikaz prve stranice dokumenta The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
  Preuzmi
PDF 311.84 KB
Znanstveni rad - Pregledni rad
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
Pharmaceuticals, 17 (2024), 10; 1313. https://doi.org/10.3390/ph17101313
Harej Hrkać, Anja; Pilipović, Kristina; Belančić, Andrej; Juretić, Lea; Vitezić, Dinko; Mršić-Pelčić, Jasenka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Harej Hrkać, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D. i Mršić Pelčić, J. (2024). The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury. Pharmaceuticals, 17. (10). doi: 10.3390/ph17101313

Harej Hrkać, Anja, et al. "The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury." Pharmaceuticals, vol. 17, br. 10, 2024. https://doi.org/10.3390/ph17101313

Harej Hrkać, Anja, Kristina Pilipović, Andrej Belančić, Lea Juretić, Dinko Vitezić i Jasenka Mršić Pelčić. "The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury." Pharmaceuticals 17, br. 10 (2024). https://doi.org/10.3390/ph17101313

Harej Hrkać, A., et al. (2024) 'The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury', Pharmaceuticals, 17(10). doi: 10.3390/ph17101313

Harej Hrkać A, Pilipović K, Belančić A, Juretić L, Vitezić D, Mršić Pelčić J. The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury. Pharmaceuticals [Internet]. 01.10.2024. [pristupljeno 06.10.2024.];17(10). doi: 10.3390/ph17101313

A. Harej Hrkać, K. Pilipović, A. Belančić, L. Juretić, D. Vitezić i J. Mršić Pelčić, "The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury", Pharmaceuticals, vol. 17, br. 10, Listopad 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:467040. [Citirano: 06.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:467040
Podaci o radu
Naslov (engleski)The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
AutorAnja Harej Hrkać
AutorKristina Pilipović
AutorAndrej Belančić
AutorLea Juretić
AutorDinko Vitezić
AutorJasenka Mršić-Pelčić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička farmakologija s toksikologijom
Sažetak (engleski)
Traumatic brain injury (TBI), which is a global public health concern, can take various forms, from mild concussions to blast injuries, and each damage type has a particular mechanism of progression. However, TBI is a condition with complex pathophysiology and heterogenous clinical presentation, which makes it difficult to model for in vitro and in vivo studies and obtain relevant results that can easily be translated to the clinical setting. Accordingly, the pharmacological options for TBI management are still scarce. Since a wide spectrum of processes, such as glucose homeostasis, food intake, body temperature regulation, stress response, neuroprotection, and memory, were demonstrated to be modulated after delivering glucagon-like peptide 1 (GLP-1) or GLP-1 receptor agonists into the brain, we aimed to speculate on their potential role in TBI management by comprehensively overviewing the preclinical and clinical body of evidence. Based on promising preclinical data, GLP-1 receptor agonists hold the potential to extend beyond metabolic disorders and address unmet needs in neuroprotection and recovery after TBI, but also other types of central nervous system injuries such as the spinal cord injury or cerebral ischemia. This overview can lay the basis for tailoring new research hypotheses for future in vitro and in vivo models in TBI settings. However, large-scale clinical trials are crucial to confirm their safety and efficacy in these new therapeutic applications.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPharmaceuticals
Brojčani podacivol. 17, br. 10, 1313
e-ISSN1424-8247
DOIhttps://doi.org/10.3390/ph17101313
URN:NBNurn:nbn:hr:184:467040
Datum objave publikacije2024-10-01
URL dokumentahttps://www.mdpi.com/1424-8247/17/10/1313
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-10-03 09:33:24